Detalhe da pesquisa
1.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
J Urol
; 210(2): 299-311, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37126069
2.
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Lancet Oncol
; 23(2): 248-258, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030333
3.
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
Future Oncol
; 18(21): 2599-2614, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608106
4.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Lancet Oncol
; 22(9): 1250-1264, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388386
5.
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
Cancer
; 127(16): 2954-2965, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951180
6.
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Prostate
; 80(1): 99-108, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31742767
7.
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Cancer
; 126(20): 4485-4497, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757302
8.
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Prostate
; 79(6): 604-613, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30663074
9.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.
J Urol
; 210(3): 411-412, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37350185
10.
11.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Lancet
; 387(10031): 1909-20, 2016 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26952546
12.
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Eur Urol Open Sci
; 50: 1-9, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37101768
13.
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
Am Soc Clin Oncol Educ Book
; 41: e190-e202, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34061561
14.
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
Clin Cancer Res
; 27(13): 3602-3609, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33795255
15.
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
J Clin Oncol
; 38(16): 1797-1806, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271672
16.
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Eur Urol
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38580518
17.
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 24(21): 5225-5232, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30012563
18.
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
Eur Urol
; 73(5): 751-759, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29248319
19.
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clin Cancer Res
; 12(20 Pt 1): 6100-5, 2006 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17062686
20.
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.
Nat Clin Pract Oncol
; 3(12): 658-67, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17139317